Back
  • ePoster
  • P029

Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies

Appointment

Date:
Time:
Talk time:
Discussion time:
Location / Stream:
Headache theatre

Poster

Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies

Session

Topic

  • New developments in prophylactic medications and acute medications
  • © Conventus Congressmanagement & Marketing GmbH